CD46: IHC Expression in Cancer and Radioligand Target Profile
CD46, CD46 molecule, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, CD46 staining is highest in prostate cancer (100% of samples positive), colorectal cancer (92% of samples positive) and gastric cancer (46% of samples positive). Clinical status: Discovery-stage (no clinical drug program).
Is CD46 the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.
Analyze CD46 freeIs CD46 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in prostate cancer, 100% of samples positive.
- ❔ Internalization: Not yet assessed.
- ⚠️ Clinical precedent: Discovery-stage (no clinical drug program)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
CD46 IHC staining by cancer type
Protein expression of CD46 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Prostate Cancer | 0.69 | High | 100% |
| Colorectal Cancer | 0.58 | High | 92% |
| Gastric Cancer | 0.21 | Medium | 46% |
| Liver Cancer | 0.19 | Low | 42% |
| Lung Cancer | 0.19 | Low | 33% |
| Pancreatic Cancer | 0.17 | Low | 33% |
| Ovarian Cancer | 0.15 | Low | 27% |
| Bladder Cancer | 0.15 | Low | 27% |
| Thyroid Cancer | 0.08 | Low | 25% |
| Breast Cancer | 0.08 | Low | 17% |
| Endometrial Cancer | 0.08 | Low | 17% |
| Cervical Cancer | 0.06 | Low | 8% |
Not detected by IHC in: skin cancer, head and neck cancer, lymphoma, melanoma, kidney cancer, neuroendocrine tumors, testicular cancer, glioma.
Is CD46 internalized?
Nuclens has not yet extracted internalization evidence for CD46. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a free analysis to pull the latest literature.
CD46 clinical trials
Discovery-stage (no clinical drug program). Nuclens hasn't indexed trials for CD46 yet. Search ClinicalTrials.gov for CD46 trials.
CD46 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See CD46 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
CD46 gene essentiality (DepMap)
CRISPR knockout effect across 1258 cancer cell lines: -0.01 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related prostate cancer radioligand targets
PSMA (FOLH1) · HER3 (ERBB3) · c-MET (MET) · EGFR · EPCAM · FAP · B7-H3 (CD276) · STEAP2
See all radioligand therapy targets in prostate cancer.
See how CD46 ranks against 15,000 targets for your indication.
Analyze CD46 freeData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.